Dx Focus: Quest Simplexa C. Diff Assay Gets FDA OK; XDx Begins AlloMap Testing ... GenomeWeb AlloMap is a non-invasive blood test that helps physicians to determine a stable heart transplant patient's risk of acute cellular rejection without using endomyocardial biopsy. The test uses quantitative real-time PCR to survey 20 genes — 11 of which ... |
